Results 31 to 40 of about 1,034,952 (285)

Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis.

Journal of Clinical Oncology, 2019
PURPOSE Gastric cancer (GC) with peritoneal metastases (PMs) is a poor prognostic evolution. Cytoreductive surgery (CRS) yields promising results, but the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) remains controversial. Here we aimed to
P. Bonnot, G. Piessen, V. Kepenekian, E. Decullier, M. Pocard, B. Meunier, J. Bereder, K. Abboud, F. Marchal, F. Quénet, D. Goéré, S. Msika, C. Arvieux, N. Pirró, R. Wernert, P. Rat, J. Gagnière, J. Lefèvre, T. Courvoisier, R. Kianmanesh, D. Vaudoyer, M. Rivoire, P. Meeus, G. Passot, O. Glehen   +24 more
semanticscholar   +1 more source

Hyperthermic Intraperitoneal Chemotherapy

Definitions, 2020
In the past, patients with peritoneal metastases have been treated only with palliative thera -py. Their state was deemed to be incurable. The median survival time was approximately two months.
Marko Hočevar, Pavel Skok
semanticscholar   +1 more source

Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis : mission possible? [PDF]

, 2017
A
Ceelen, Wim, Dakwar, George, De Smedt, Stefaan, Remaut, Katrien, Shariati, Molood, Willaert, Wouter   +5 more
core   +2 more sources

The next steps in improving the outcomes of advanced ovarian cancer [PDF]

, 2015
Worldwide ovarian cancer affects over 200,000 women per year. Overall survival rates are poor due to two predominate reasons. First, the majority of patients present with advanced disease creating significant difficulty with effecting disease eradication.
Blagden, S, Fotopoulou, C, Gabra, H, Openshaw, MR   +3 more
core   +1 more source

Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative

World Journal of Gastrointestinal Oncology, 2020
BACKGROUND Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis can be performed in two ways: Open or closed abdominal technique. AIM To evaluate the impact of HIPEC method on post-operative and
J. Leiting, J. Cloyd, A. Ahmed, K. Fournier, Andrew J. Lee, S. Dessureault, Seth I. Felder, J. Veerapong, J. Baumgartner, C. Clarke, H. Mogal, C. Staley, Mohammad Y Zaidi, Sameer H. Patel, Syed A. Ahmad, Ryan J. Hendrix, L. Lambert, D. Abbott, C. Pokrzywa, M. Raoof, C. LaRocca, F. Johnston, Jonathan B. Greer, T. Grotz   +23 more
semanticscholar   +1 more source

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for patients with peritoneal metastases from endometrial cancer [PDF]

, 2017
Background: More information is needed for selection of patients with peritoneal metastases from endometrial cancer (EC) to undergo cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). Methods: This study analyzed clinical,
Biacchi, Daniele, Christopoulou, Athina, Ciardi, Antonio, Cornali, Tommaso, Efstathiou, Elias, Framarino dei Malatesta, Marialuisa, Kopanakis, Nikolaos, Sammartino, Paolo, Spagnoli, Alessandra, Spiliotis, John   +9 more
core   +1 more source

Targeting the tumor microenvironment in colorectal peritoneal metastases

, 2020
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim, De Wever, Olivier, Heriot, Alexander G., Narasimhan, Vignesh, Ramsay, Robert G.   +4 more
core   +1 more source

Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer [PDF]

, 2019
Patients with advanced ovarian cancer develop recurrence despite initial treatment response to standard treatment of surgery and intravenous/intraperitoneal (IP) chemotherapy, partly due to a limited peritoneal exposure time of chemotherapeutics ...
Ceelen, Wim, De Clercq, Kaat, De Wever, Olivier, Descamps, Benedicte, Hoorens, Anne, Vermeulen, An, Vervaet, Chris, Xie, Feifan   +7 more
core   +2 more sources

Aerosolization of nanotherapeutics as a newly emerging treatment regimen for peritoneal carcinomatosis

, 2019
Recent advances in locoregional chemotherapy have opened the door to new approaches for the clinical management of peritoneal carcinomatosis (PC) by facilitating the delivery of anti-neoplastic agents directly to the tumor site, while mitigating adverse ...
Ceelen, Wim, De Smedt, Stefaan, Remaut, Katrien, Shariati, Molood, Willaert, Wouter   +4 more
core   +1 more source

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Diagnostics, 2020
Hyperthermic intraperitoneal chemotherapy (HIPEC) in conjunction with cytoreductive surgery (CRS) holds promise as an adjunctive treatment strategy in malignancies affecting the peritoneal surface, effectively targeting remaining microscopic residual ...
McKayla J. Riggs, P. Pandalai, Joseph Kim, C. Dietrich   +3 more
semanticscholar   +1 more source